PRCT Stock — PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation (PRCT)

PRCT is a Stock. Total return is -54.0% over the past 5 years, 136.4 points behind SPY at 82.4%.

PROCEPT BioRobotics Corporation is a surgical robotics company that develops and sells robotic systems for minimally invasive urologic procedures, primarily treating benign prostatic hyperplasia through its AquaBeam and HYDROS robotic platforms. The company does not currently distribute dividends. It may appeal to growth-oriented investors seeking exposure to the medical device and surgical robotics sector.

PRCT performance versus SPY

Price and return data through 2026-09-18.

Total return is -54.0% over the past 5 years, 136.4 points behind SPY at 82.4%. Over the past year its total return — price change plus distributions reinvested — is -49.2%. Its deepest 1-year drawdown was 57.4%.

PRCT key facts

Asset type

Stock

Asset class

Equity

Inception date

09/15/2021

Distribution frequency

None

Last close

$19.30 (as of 2026-09-18)

Market cap

$1,098,533,689

Average volume

1491200.0

Beta

0.902

Payout ratio

0.0

Forward P/E

0.0

EPS

$-1.79

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

PRCT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 57.4%.

Who may consider PRCT — and who may not

It is a weaker fit for investors who need monthly cash flow (PRCT does not currently distribute); investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

Frequently asked questions